4D Path has closed the first tranche of a strategic financing round, marking its initial funding. This capital will accelerate the development of treatment predictive biomarkers for both clinical use and Biopharma partnerships. The company aims to leverage its physics-informed approach to personalize cancer care by predicting tumor response to therapy.
